GoodRx Holdings, Inc.

GDRX Healthcare Health Information Services

GoodRx Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $796.9 million, up 0.57% from fiscal 2024. In the quarter to June 2026, revenue fell 1.31%, EPS fell 25.0%, free cash flow grew 112.5% and total debt was flat, each against the same quarter a year earlier.

3.36 0.15 −4.27%
Market cap
$1.2B
P/E
62.7×
Fwd P/E
30.9×
Dividend yield
—
F-score
6/9
Altman Z
0.44
Beneish M
−2.40
Dividend safety
n/a

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Revenue
796.85 792.32 750.27 766.55 745.42 550.70 388.22 249.52 157.24 99.38
Revenue Growth
0.57% 5.61% (2.12%) 2.83% 35.36% 41.85% 55.59% 58.69% 58.23% (36.80%)
Cost of Revenue
57.60 48.22 66.93 65.08 46.72 29.59 14.02 6.04 12.17 10.32
Gross Profit
739.26 744.11 683.34 701.48 698.71 521.11 374.21 243.49 145.07 89.06
R&D Expenses
121.03 123.75 135.84 143.14 125.86 61.82 29.30 43.89 11.50 5.74
SG&A Expenses
445.52 484.98 466.84 502.42 524.90 716.59 191.66 112.54 83.26 64.40
Operating Income
87.49 65.85 (27.01) 1.74 13.41 (275.72) 139.68 77.25 — —
Interest Expense (Operating)
— — — — — — — — 6.97 3.54
Non-operating Income/Expense
(30.95) (34.39) (28.56) (24.97) (23.58) (27.73) (56.70) (24.90) 3.67 (0.01)
Non-operating Interest Expenses
42.61 52.92 56.73 34.24 23.64 27.91 49.57 22.19 0.02 0.02
EBT
56.54 31.46 (55.57) (23.23) (10.18) (303.45) 82.98 52.35 39.70 15.10
Income Tax Provision
26.10 15.07 (46.70) 9.60 15.08 (9.83) 16.93 8.56 10.93 6.19
Income after Tax
30.44 16.39 (8.87) (32.83) (25.25) (293.62) 66.05 43.79 — —
Dividends (Preferred)
— — — — — — 23.30 29.57 — —
Net Income Common
30.44 16.39 (8.87) (32.83) (25.25) (293.62) 42.75 14.23 8.84 (7.77)
EPS (Basic)
0.09 0.04 (0.02) (0.08) (0.06) (1.07) 0.29 0.39 0.02 (0.02)
EPS (Diluted)
0.09 0.04 (0.02) (0.08) (0.06) (1.07) 0.29 0.37 0.02 (0.02)
Shares (Basic, Weighted)
356.33 385.74 410.32 412.86 409.98 274.70 226.61 111.84 385.38 385.38
Shares (Diluted, Weighted)
356.97 392.17 410.32 412.86 409.98 274.70 231.21 118.34 385.38 385.38
Gross Margin
92.77% 93.91% 91.08% 91.51% 93.73% 94.63% 96.39% 97.58% 92.26% 89.62%
EBIT Margin
10.98% 8.31% (3.60%) 0.23% 1.80% (50.07%) 35.98% 30.96% 63.99% 38.07%
EBT margin
7.10% 3.97% (7.41%) (3.03%) (1.37%) (55.10%) 21.37% 20.98% 25.25% 15.20%
Net Profit Margin
3.82% 2.07% (1.18%) (4.28%) (3.39%) (53.32%) 11.01% 5.70% 5.62% (7.82%)
Free Cash Flow Margin
11.78% 14.33% 11.00% 11.95% 19.36% 17.34% 19.97% 16.75% 0.00% 0.00%
EBITDA
174.48 137.88 84.04 59.33 51.39 (253.90) 156.63 88.30 59.41 28.01
EBIT
87.49 65.85 (27.01) 1.74 13.41 (275.72) 139.68 77.25 100.61 37.83
Income from Continuous Operations
30.44 16.39 (8.87) (32.83) (25.25) (293.62) 66.05 43.79 — —
Consolidated Net Income/Loss
30.44 16.39 (8.87) (32.83) (25.25) (293.62) 66.05 43.79 8.84 (7.77)
EPS (Basic, from Continuous Ops)
0.09 0.04 (0.02) (0.08) (0.06) (1.07) 0.29 0.39 — —
EPS (Basic, Consolidated)
0.09 0.04 (0.02) (0.08) (0.06) (1.07) 0.29 0.39 — —
EPS (Diluted, from Cont. Ops)
0.09 0.04 (0.02) (0.08) (0.06) (1.07) 0.29 0.37 — —
Shares (Diluted, Average)
356.97 392.17 410.32 412.86 409.98 274.70 — — — —
EPS (Diluted, Consolidated)
0.09 0.04 (0.02) (0.08) (0.06) (1.07) 0.29 0.37 — —
EBITDA Margin
21.90% 17.40% 11.20% 7.74% 6.89% (46.10%) 40.35% 35.39% 37.78% 28.18%
Operating Cash Flow Margin
21.07% 23.21% 18.43% 19.15% 23.98% 23.85% 21.45% 18.14% 0.00% 0.00%

Fold the line items

In millions of $ except per-share values · columns are period end dates